Risedronate

Risedronate is a bisphosphonate active pharmaceutical ingredient used in the treatment of osteoporosis and Paget's disease. Mediocon Inc supplies high-purity Risedronate API conforming to IP / BP / EP / USP specifications from our GMP-certified facility in Aurangabad, Maharashtra, India.

Risedronate inhibits osteoclast-mediated bone resorption by binding to hydroxyapatite crystals in bone. It is a first-line treatment for postmenopausal osteoporosis, glucocorticoid-induced osteoporosis, and Paget's disease of bone.

Key Features

• High-purity pharmaceutical grade API
• IP / BP / EP / USP compliant
• Full CoA and MSDS documentation
• GMP certified manufacturing

Applications

• Postmenopausal osteoporosis treatment
• Glucocorticoid-induced osteoporosis
• Paget's disease of bone
• Bone density pharmaceutical formulations

Why Choose Mediocon

• ISO 9001:2015 & GMP certified manufacturing
• Consistent batch-to-batch quality with full CoA
• Export-ready documentation: COO, MSDS, DMF
• Flexible MOQ for both R&D and commercial scale
• Dedicated QA support for regulatory filings